Screening
Genotyping + quality control + breeding values + composite index + herd ranking.
- Who it suits
- Operations doing genomic testing for the first time.
- Delivery time
- 4–6 weeks
Services
Clinical Genomics Line
Our clinical line provides interpretation and reporting solutions for clinical laboratories and genetic diagnostic centers. This line is completely separate from the livestock line at the data, infrastructure, and documentation level.
Pharmacogenomics (PGx)
Enables drug–gene interactions to be translated into clinical decision support.
| Item | Scope |
|---|---|
| Analysis scope | Identification of the genes and haplotypes involved in drug metabolism, diplotype assignment, and phenotype prediction. |
| Guideline basis | Interpretation based on international pharmacogenomic consortium guidelines. The guideline used and its version are stated in every report. |
| Report output | Recommendation level, evidence level, and a clinical note for each gene–drug pair. The recommendation and the evidence level are presented in separate columns. |
| Uncertainty management | Cases where a diplotype cannot be assigned or the evidence level is insufficient are stated explicitly; no forced interpretation is made. |
- Item
- Analysis scope
- Scope
- Identification of the genes and haplotypes involved in drug metabolism, diplotype assignment, and phenotype prediction.
- Item
- Guideline basis
- Scope
- Interpretation based on international pharmacogenomic consortium guidelines. The guideline used and its version are stated in every report.
- Item
- Report output
- Scope
- Recommendation level, evidence level, and a clinical note for each gene–drug pair. The recommendation and the evidence level are presented in separate columns.
- Item
- Uncertainty management
- Scope
- Cases where a diplotype cannot be assigned or the evidence level is insufficient are stated explicitly; no forced interpretation is made.
Clinical Exome (WES / CES)
| Item | Scope |
|---|---|
| Analysis scope | Variant calling, annotation, filtering, and prioritization across whole-exome and clinical exome data. |
| Classification | Evaluation according to internationally accepted variant classification criteria; the rationale for applying each criterion is recorded. |
| Population frequency | Frequency information from reference population databases; both the raw value and the threshold-based evaluation are retained. |
| Phenotype matching | Matching and prioritizing candidate genes against clinical finding terms. |
| Update | Variant databases are updated regularly; classification changes are tracked and can be reported. |
- Item
- Analysis scope
- Scope
- Variant calling, annotation, filtering, and prioritization across whole-exome and clinical exome data.
- Item
- Classification
- Scope
- Evaluation according to internationally accepted variant classification criteria; the rationale for applying each criterion is recorded.
- Item
- Population frequency
- Scope
- Frequency information from reference population databases; both the raw value and the threshold-based evaluation are retained.
- Item
- Phenotype matching
- Scope
- Matching and prioritizing candidate genes against clinical finding terms.
- Item
- Update
- Scope
- Variant databases are updated regularly; classification changes are tracked and can be reported.
Technical and Quality Infrastructure
- The platform has a modular architecture built on Spring Boot 3.4.x / Java 21 / Spring Modulith.
- The analysis pipeline is written in Nextflow DSL2; every run is versioned and reproducible.
- The quality and documentation system is structured to the Class C requirements of in vitro diagnostic medical device regulation. The documentation file is shared on request.
- Clinical safety red lines are defined and continuously verified through automated tests. No interpretation is produced for a variant that cannot be verified.
Service Packages
Packages are defined according to typical needs and can be combined. Pricing is finalized at the proposal stage based on the number of animals, panel density, and scope of service; the current price list can be requested from info@vethia.com.tr.
Screening + Defect
Genetic defect screening is added to the Screening package.
- Who it suits
- Breeding-stock producers.
- Delivery time
- 4–6 weeks
Breeding Program
A mating plan, relatedness management, and a results consultation are added to the Screening + Defect package.
- Who it suits
- Operations actively running a breeding program.
- Delivery time
- 5–7 weeks
Annual Consulting
Breeding Program + platform access + annual progress report + periodic consultations.
- Who it suits
- Those who want to run an ongoing program.
- Delivery time
- Annual
Molecular Diagnostics
PCR panels and antibiotic resistance tests; single or periodic monitoring.
- Who it suits
- Clinics, operations, and stud farms.
- Delivery time
- Per panel
Association Program
Multi-operation platform account, batch analysis, association-level reporting, member training.
- Who it suits
- Breeder associations and cooperatives.
- Delivery time
- Project-based
R&D Project
GWAS, genomic prediction, panel design, pipeline development, publication-ready output.
- Who it suits
- Universities and research institutions.
- Delivery time
- Project-based
Clinical Platform
PGx and/or clinical exome interpretation infrastructure, setup, and training.
- Who it suits
- Clinical laboratories.
- Delivery time
- Project-based
How We Work
01
Needs consultation
1 day
02
Sample plan
2–3 days
03
Sample collection and acceptance
Depends on the operation
04
Genotyping
2–4 weeks
05
Quality control and analysis
3–5 business days
06
Reporting
2–3 business days
07
Results consultation
1 day
Frequently Asked Questions
Identification of the genes and haplotypes involved in drug metabolism, diplotype assignment, and phenotype prediction.
Evaluation according to internationally accepted variant classification criteria; the rationale for applying each criterion is recorded.
The livestock and clinical lines are separated at the data, infrastructure, and documentation level. The two fields have different regulatory regimes and are not mixed.
Contact and Getting Started
The process begins with a non-binding needs consultation. In this meeting, we discuss your herd's current status, your goals, and your budget framework; together we determine the package that suits you.
0532 287 04 87WhatsAppinfo@vethia.com.trKocatepe Mah. Olcay Sok. No: 7, 34045 Bayrampaşa / Istanbul, Türkiye
Request a consultation